Raymond James lowers Stryker stock price target on hips and knees slowdown
Raymond James cut Stryker's (NYSE:SYK) price target to $323 from $330, citing a slowdown in the hips and knees market. Stryker reported Q3 revenue of $6.52B, below estimates, and lowered 2026 revenue guidance. Analysts revised earnings downward, but some see the stock as undervalued. Stryker's management highlighted a strong pipeline and a $3B share repurchase program.
How this was made
The 30-second read
Why it matters
The guidance reduction and lower price target signal a shift in growth expectations for the orthopaedic market.
Market read
Analyst downgrades and guidance cuts are likely to drive short‑term downside for SYK.
What to watch
Strength in MedSurg and neurotechnology segments may offset orthopaedic weakness.
Background
Stryker reported Q3 revenue of $6.52 bn, slightly below estimates, and EPS of $3.52 versus $3.55 consensus.
Ticker impact
Raymond James lowered Stryker's price target to $323 and the company cut its 2026 revenue guidance by 200 bps, citing a slowdown in hips and knees market.
likely pressure as the market prices in weaker growth outlook
Analyst downgrade and revised guidance directly affect valuation expectations.
Market effects
Orthopaedic device segment may face broader headwinds, potentially impacting peers.
U.S. medical‑device sector could see modest pullback.
Limited to Stryker and its immediate competitors.
Counterpoint
Despite the slowdown, Stryker's $3 billion share repurchase could support the stock.
Key entities
- analystRaymond James
Equity research firm that lowered the price target.
- analystCitizens
Adjusted price target to $390.
- analystNeedham
Adjusted price target to $359.
